A consensus statement for safety monitoring guidelines of treatments for major depressive disorder

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 9, 2011, Pages 712-725

  Dodd, Seetal ^a,b   Malhi, Gin S ^c   Tiller, John ^b   Schweitzer, Isaac ^b   Hickie, Ian ^d   Khoo, Jon Paul ^e   Bassett, Darryl L ^f,g   Lyndon, Bill ^c   Mitchell, Philip B ^h,i   Parker, Gordon ^h,i   Fitzgerald, Paul B ^j   Udina, Marc ^k   Singh, Ajeet ^a,b   Moylan, Steven ^a   Giorlando, Francesco ^d   Doughty, Carolyn ^l   Davey, Christopher G ^m   Theodoros, Michael ⁿ   Berk, Michael ^a,d,m,o  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Level 2/54 Jephson St   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF NOTRE DAME   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ BLACK DOG INSTITUTE   (Australia)

^j University of Barcelona ^*  (Australia)

^k UNIVERSITY OF BARCELONA   (Spain)

^l UNIVERSITY OF OTAGO   (New Zealand)

^m THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

ⁿ New Farm Clinic   (Australia)

^o FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALANINE AMINOTRANSFERASE; AMFEBUTAMONE; AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HYDROCORTISONE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PERPHENAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; THYROTROPIN; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VITAMIN D; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLOOD DYSCRASIA; BLOOD EXAMINATION; BLURRED VISION; BODY MASS; BODY TEMPERATURE; BONE DENSITY; CARDIOVASCULAR DISEASE; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; ELECTROCONVULSIVE THERAPY; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTHYROIDISM; HYPONATREMIA; HYPOTHYROIDISM; INCIDENCE; INCREASED APPETITE; INSOMNIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR DEPRESSION; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATIENT MONITORING; PATIENT SAFETY; PHARMACOGENETICS; PRACTICE GUIDELINE; QT PROLONGATION; REVIEW; RISK FACTOR; SCREENING; SEASONAL AFFECTIVE DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREMOR; URINARY DYSFUNCTION; VERTIGO; VITAMIN DEFICIENCY; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; XEROSTOMIA; YAWNING;

ANTIDEPRESSIVE AGENTS; CONSENSUS; DEPRESSIVE DISORDER, MAJOR; HEALTH STATUS; HUMANS; PATIENT SAFETY; TREATMENT OUTCOME;

EID: 80052509442     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2011.595686     Document Type: Review

References (173)

1. Heo M, Murphy CF, Fontaine KR, Bruce ML, Alexopoulos GS. Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050. Int J Geriatr Psychiatry 2008; 23:1266-1270.
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105.
3. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neu-ropsychopharmacol 2005; 15:357-376.
4. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2009; 43:594-605.
5. Worthy KC, Governale LA. Trends in outpatient prescription usage in the U.S., 2002-2005. Poster presented at the 12th Annual FDA Science Forum, Washington, DC, April 18-20, 2006, board no. I-13.
6. Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry 2010; 44:513-519.
7. Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008; 45:25-89.
8. Mago R, Mahajan R, Thase ME. Medically serious adverse effects of newer antidepressants. Curr Psychiatry Rep 2008; 10:249-257.
9. Uher R, Farmer A, Henigsberg N et al. Adverse reactions to anti-depressants. Br J Psychiatry 2009; 195:202-210.
10. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13:855-870.
11. Parker G, Fink M, Shorter E et al. Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry 2010; 167:745-747.
12. Pacher P, Kecskemeti V. Cardiovascular side effects of new anti-depressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 2004; 10:2463-2475.
13. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmacher T. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 2004; 38:485-489.
14. Carvajal Garcia-Pando A, Garcia del Pozo J, Sanchez AS, Velasco MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63: 135-137.
15. Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepres-sant treatment. J Clin Psychiatry 2004; 65:742-749.
16. Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786-1789.
17. Franco-Bronson K. The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am 1996; 19: 329-350.
18. Sommer BR, Fenn H, Pompei P, DeBattista C, Lembke A, Wang P, Flores B. Safety of antidepressants in the elderly. Expert Opin Drug Saf 2003; 2:367-383.
19. Berk M, Dodd S. Antidepressants and adolescents: the bipolar confound? Hum Psychopharmacol 2005; 20:1-2.
20. Wisner KL, Sit DK, Hanusa BH et al. Major depression and anti-depressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557-566.
21. Williams LJ, Pasco JA, Henry MJ et al. Lifetime psychiatric disorders and body composition: a population-based study. J Affect Disord 2009; 118:173-179.
22. Turvey CL, Schultz SK, Beglinger L, Klein DM. A longitudinal community-based study of chronic illness, cognitive and physical function, and depression. Am J Geriatr Psychiatry 2009; 17: 632-641.
23. Maes M, Leonard B, Fernandez A et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Prog Neuropsychopharma-col Biol Psychiatry 2011; 35:659-663.
24. Berk M, Parker G. The elephant on the couch: side-effects of psychotherapy. Aust N Z J Psychiatry 2009; 43:787-794.
25. Breidenbach T, Hoffmann M W, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355:1912.
26. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane Database Syst Rev 2009:CD004366.
27. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 2000; 343:1355-1361.
28. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007; 120:799-806.
29. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
30. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11:559-595.
31. Berk M, Fitzsimons J, Lambert T et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs 2007; 21:117-127.
32. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004; 38:389-407.
33. Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 2009:8-26.
34. Coulson CE, Williams LJ, Henry MJ et al. Patterns of alcohol use and associated physical and lifestyle characteristics according to new Australian guidelines. Aust N Z J Psychiatry 2010; 44: 946-951.
35. Pasco JA, Williams LJ, Jacka FN et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br J Psychiatry 2008; 193:322-326.
36. Berk M, Ng F, Wang WV et al. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord 2008; 110:126-134.
37. Jacka FN, Pasco JA, Williams LJ et al. Lower levels of physical activity in childhood associated with adult depression. J Sci Med Sport 2011; 14:222-226.
38. Pasco JA, Williams LJ, Jacka FN et al. Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. Int Psychogeriatr 2010:1-7.
39. Jacka FN, Kremer PJ, Leslie ER et al. Associations between diet quality and depressed mood in adolescents: results from the Australian Healthy Neighbourhoods Study. Aust N Z J Psychiatry 2010; 44:435-442.
40. Jacka FN, Pasco JA, Mykletun A et al. Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167:305-311.
41. Batterham PJ, Christensen H, Mackinnon AJ. Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach. BMC Psychiatry 2009; 9:75.
42. Zuithoff N P, Vergouwe Y, King M et al. A clinical prediction rule for detecting major depressive disorder in primary care: the PRE-DICT-NL study. Fam Pract 2009; 26:241-250.
43. Berk M, Jacka FN, Williams LJ, Ng F, Dodd S, Pasco JA. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. Aust N Z J Psychiatry 2008; 42:874-878.
44. Berk M, Sanders KM, Pasco JA et al. Vitamin D deficiency may play a role in depression. Med Hypotheses 2007; 69:1316-1319.
45. Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Mykletun A. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry 2009; 43:45-52.
46. Szewczyk B, Poleszak E, Sowa-Kucma M et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 2008; 60:588-589.
47. Robertson MM, Katona CLE. Depression and physical illness. Chichester: Wiley, 1997.
48. Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendo-crinol 2008; 20:1101-1114.
49. Fountoulakis KN, Kantartzis S, Siamouli M et al. Peripheral thyroid dysfunction in depression. World J Biol Psychiatry 2006; 7:131-137.
50. Carta MG, Hardoy MC, Garofalo A et al. Association of chronic hepatitis C with major depressive disorders: irrespective of inter-feron-alpha therapy. Clin Pract Epidemol Ment Health 2007; 3:22.
51. Liangpunsakul S, Qi R, Crabb DW, Witzmann F. Relationship between alcohol drinking and aspartate aminotransferase:alanine aminotransferase (AST:ALT) ratio, mean corpuscular volume (MCV), gamma-glutamyl transpeptidase (GGT), and apolipopro-tein A1 and B in the U.S. population. J Stud Alcohol Drugs 2010; 71:249-252.
52. Shacham E, Nurutdinova D, Satyanarayana V, Stamm K, Overton ET. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS 2009; 23: 949-955.
53. Bailey DE Jr, Landerman L, Barroso J et al. Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C. Psy-chosomatics 2009; 50:138-146.
54. Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg Infect Dis 2007; 13:479-481.
55. Miller AH, Silberstein C, Asnis GM et al. Epstein-Barr virus infection and depression. J Clin Psychiatry 1986; 47:529-530.
56. Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005; 95:317-321.
57. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997; 43: 529-534.
58. Bennett BK, Hickie IB, Vollmer-Conna US et al. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Aust N Z J Psychiatry 1998; 32:180-186.
59. Martin-Santos R, Diez-Quevedo C, Castellvi P et al. De novo depression and anxiety disorders and influence on adherence during PEGinterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008; 27:257-265.
60. Dewhurst K. The neurosyphilitic psychoses today. A survey of 91 cases. Br J Psychiatry 1969; 115:31-38.
61. Ortega-Hernandez OD, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci 2009; 1173:600-609.
62. Fergusson DM, Boden JM, Horwood LJ. Tests of causal links between alcohol abuse or dependence and major depression. Arch Gen Psychiatry 2009; 66:260-266.
63. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917-1921.
64. Aubin HJ. Management of emergent psychiatric symptoms during smoking cessation. Curr Med Res Opin 2009; 25:519-525.
65. Kaminer Y, Connor DF, Curry J F. Treatment of comorbid adolescent cannabis use and major depressive disorder. Psychiatry (Edg-mont) 2008; 5:34-39.
66. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001; 62S16:18-25.
67. Manthey L, van Veen T, Giltay EJ et al. Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA). Br J Clin Pharmacol 2011; 71:263-272.
68. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 2007; 99:213-220.
69. Aharonovich E, Nguyen HT, Nunes E V. Anger and depressive states among treatment-seeking drug abusers: testing the psychop-harmacological specificity hypothesis. Am J Addict 2001; 10: 327-334.
70. Bahrke MS, Yesalis CE, 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med 1996; 22:367-390.
71. Frye CA. Steroids, reproductive endocrine function, and affect. A review. Minerva Ginecol 2009; 61:541-562.
72. Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions. Harv Rev Psychiatry 1997; 5:214-226.
73. Schaefer M, Engelbrecht MA, Gut O et al. Interferon alpha (IFNal-pha) and psychiatric syndromes: a review. Prog Neuropsychophar-macol Biol Psychiatry 2002; 26:731-746.
74. Kanner AM, Wuu J, Faught E, Tatum WOt, Fix A, French JA. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4:548-552.
75. Hollister LE. Drug-induced psychiatric disorders and their management. Med Toxicol 1986; 1:428-448.
76. Johnson DA. Drug-induced psychiatric disorders. Drugs 1981; 22:57-69.
77. Flaherty JA. Psychiatric complications of medical drugs. J Fam Pract 1979; 9:243-251.
78. Whitlock FA. Adverse psychiatric reactions to modern medication. Aust N Z J Psychiatry 1981; 15:87-103.
79. Mithal A, Wahl D, Bonjour J et al, on behalf of IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009.
80. Pasco J, Henry M, Nicholson G, Sanders K, Kotowicz M. Vitamin D status of women in the Geelong Osteoporosis Study: association with diet and casual exposure to sunlight. Med J Aust 2001; 175:401-405.
81. van der Mei I, Ponsonby A-L, Engelsen O et al. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ Health Per-spect 2007; 115:1132-1139.
82. McGrath J, Kimlin M, Saha S, Eyles D, Parisi A. Vitamin D insuf-ficiency in south-east Queensland. Med J Aust 2001; 174:150-151.
83. Park S, Johnson M. Living in low-latitude regions in the United States does not prevent poor vitamin D status. Nutr Rev 2005; 63:203-209.
84. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ' Vascular depression'hypothesis. Arch Gen Psychiatry 1997; 54:915-922.
85. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schrizophr Res 1999; 40:173-177.
86. Milaneschi Y, Shardell M, Corsi A et al. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endo-crinol Metab 2010; 95:3225-3233.
87. Ganji V, Milone C, Cody MM, McCarty F, Wang YT. Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey. Int Arch Med 2010; 3:29.
88. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009; 105:158-161.
89. Sanders KM, Stuart AL, Williamson E et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry 2011; 198:357-364.
90. Gariballa S, Forster S. Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial. Clin Nutr 2007; 26:545-551.
91. Walker JG, Mackinnon AJ, Batterham P et al. Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial. Br J Psychiatry 2010; 197:45-54.
92. Roberts SH, Bedson E, Hughes D et al. Folate augmentation of treatment-evaluation for depression (FolATED): protocol of a randomised controlled trial. BMC Psychiatry 2007; 7:65.
93. Schweitzer I, Tuckwell V, O'Brien J, Ames D. Is late onset depression a prodrome to dementia? Int J Geriatr Psychiatry 2002; 17:997-1005.
94. Wright SL, Persad C. Distinguishing between depression and dementia in older persons: neuropsychological and neuro-pathological correlates. J Geriatr Psychiatry Neurol 2007; 20: 189-198.
95. O'Brien J, Ames D, Chiu E, Schweitzer I, Desmond P, Tress B. Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ 1998; 317:982-984.
96. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009; 6:16-18.
97. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
98. Heiskanen TH, Niskanen LK, Hintikka JJ et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006; 67:1422-1427.
99. Richter N, Juckel G, Assion HJ. Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci; 260:41-49.
100. Takeuchi T, Nakao M, Nomura K et al. Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study. Diabetes Metab Res Rev 2009; 25:762-767.
101. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155:4-11.
102. Murray JB. Cardiac disorders and antidepressant medications. J Psychol 2000; 134:162-168.
103. Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 2003; 5:153-160.
104. O'Brien S, McKeon P, O'Regan M, O'Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992; 12:104-109.
105. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64:192-197.
106. Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci 2009; 1179:19-40.
107. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4:182-188.
108. Marchesi C, Bertoni S, Maggini C. Major and minor depression in pregnancy. Obstet Gynecol 2009; 113:1292-1298.
109. Dodd S, Berk M. The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf2006; 1:25-33.
110. Dodd S, Berk M. The pharmacology of bipolar disorder during pregnancy and breastfeeding. Expert Opin Drug Saf2004; 3:221-229.
111. Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29:822-831.
112. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47:75-85.
113. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25:193-200.
114. Singh A. Pharmacogenomics: the potential of genetically guided prescribing. Aust Fam Physician 2007; 36:820-824.
115. Laje G, Paddock S, Manji H et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164:1530-1538.
116. Malhi GS, Lagopoulos J. Making sense of neuroimaging in psychiatry. Acta Psychiatr Scand 2008; 117:100-117.
117. Loo C, Trollor J, Alonzo A, Rendina N, Kavess R. Mental health legislation and psychiatric treatments in NSW: electroconvulsive therapy and deep brain stimulation. Australas Psychiatry 2010; 18:417-425.
118. Tiller JWG, Lyndon RW Electroconvulsive therapy: an Australasian guide Fitzroy, VIC: Australian Postgraduate Medicine, 2003.
119. McDermott B, Baigent M, Chanen A et al. beyondblue Expert Working Committee (2010) Clinical practice guidelines: Depression in adolescents and young adults. Melbourne: beyondblue: the national depression initiative, 2010. Available at URL: http://www.beyondblue.org.au/index.aspx?link-id = 6.1247&tmp = Fil eDownload&fid = 1625
120. The Australian Government Department of Health and Ageing. The Living Is For Everyone (LIFE) framework. Canberra: Commonwealth of Australia, 2007.Available at URL: http://www. livingisforeveryone.com.au/IgnitionSuite/ uploads/docs/LIFE- framework-web.pdf
121. Risselada AJ, Mulder H, Heerdink ER, Grube AM, Wilmink F W, Egberts TC. The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study. J Clin Psychophar-macol 30:207-209.
122. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988; 26:265-271.
123. Hainer V, Kabrnova K, Aldhoon B, Kunesova M, Wagenknecht M. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann N Y Acad Sci 2006; 1083:252-269.
124. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf 2008; 31:597-607.
125. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61S11:37-41.
126. Seo HJ, Jung YE, Woo YS, Jun TY, Chae JH, Bahk WM. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psy-chopharmacol 2009; 24:135-143.
127. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052.
128. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89:1363-1372.
129. Tamene A, Sattiraju S, Wang K, Benditt DG. Brugada-like elec-trocardiography pattern induced by severe hyponatraemia. Europace 2010; 12:905-907.
130. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001; 3:K70-K80.
131. Rouleau F, Asfar P, Boulet S et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12:61-65.
132. Civalier KA, Krahn LE, Agrwal N. Repeated episodes of neutrope-nia triggered by mirtazapine. Psychosomatics 2009; 50:299-300.
133. Andersohn F, Konzen C, Bronder E, Klimpel A, Garbe E. Cita-lopram-induced bleeding due to severe thrombocytopenia. Psy-chosomatics 2009; 50:297-298.
134. Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003; 2:249-262.
135. Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002; 35:112-115.
136. Pompili M, Tittoto P, Masciana R, Gasbarrini G, Rapaccini GL. Acute hepatitis associated with use of paroxetine. Intern Emerg Med 2008; 3:275-277.
137. Colakoglu O, Tankurt E, Unsal B et al. Toxic hepatitis associated with paroxetine. Int J Clin Pract 2005; 59:861-862.
138. Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. Sertraline hepa-totoxicity: report of a case and review of the literature. Dig Dis Sci 2009; 54:1589-1591.
139. Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003; 48:939-944.
140. Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 1996; 153:580.
141. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, Kirchner J P. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999; 74:692-694.
142. Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. BMJ 1989; 299:519.
143. Hui CK, Yuen MF, Wong WM, Lam SK, Lai CL. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002; 35:270-271.
144. Adetunji B, Basil B, Mathews M, Osinowo T. Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes. Ann Pharmacother 2007; 41:359.
145. Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. J Med Case Reports 2007; 1:88.
146. Detry O, Delwaide J, De Roover A et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. Transplant Proc 2009; 41:3435-3436.
147. Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ 1994; 309:378.
148. McIntyre RS, Panjwani ZD, Nguyen HT et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008; 4:281-285.
149. Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 2009; 45:599-608.
150. DeSanty K P, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother 2007; 41:1201-1211.
151. Kostrubsky SE, Strom SC, Kalgutkar AS et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006; 90:451-459.
152. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomel-atine. Hum Psychopharmacol 25:95-102.
153. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485.
154. Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA. Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report. Arq Neuropsiquiatr 2006; 64:142-145.
155. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxet-ine or paroxetine in elderly people. Br J Clin Pharmacol 1999; 47:211-217.
156. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998; 12:396-400.
157. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Ass J 1996; 155:519-527.
158. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharma-cother 2002; 36:1558-1563.
159. Nirmalani A, Stock SL, Catalano G. Syndrome of inappropriate antidiuretic hormone associated with escitalopram therapy. CNS Spectr 2006; 11:429-432.
160. Stovall R, Brahm NC, Crosby KM. Recurrent episodes of serot-onin-reuptake inhibitor-mediated hyponatremia in an elderly patient. Consult Pharm 2009; 24:765-768.
161. Bavbek N, Kargili A, Akcay A, Kaya A. Recurrent hyponatremia associated with citalopram and mirtazapine. Am J Kidney Dis 2006; 48:e61-62.
162. Koelkebeck K, Domschke K, Zwanzger P, Hetzel G, Lang D, Arolt V. A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine. World J Biol Psychiatry 2009; 10:609-611.
163. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004; 327:109-111.
164. Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticon-vulsants in elderly patients with psychiatric disorders: oxcar-bazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007; 6:133-145.
165. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, Stash-enko P. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004; 19:1420-1431.
166. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008; 23:84-87.
167. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008; 28:384-391.
168. Ziere G, Dieleman J P, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibiting antidepres-sants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008; 28:411-417.
169. Dodd S, Hodge J, Williams L, Berk M, Nicholson G. The effect of SSRIs on osteoclast formation and functioning. Poster presented at the 26th Collegium Internationale Neuro-Psychophar-macologicum Congress, Munich, 13-17 July 2008. Int J Neuropsychopharmacol 2008; 11:130.
170. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3:13-37.
171. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29:S1-9.
172. Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr Drug Metab 2006; 7:127-133.
173. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacoki-netic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30:1206-1227.